« Back to Record
Citation APA

Attal, M., Garderet, L., Roussel, M., Payen, C., Mathiot, C., Fermand, J.-P., Meuleman, N., Rollet, S., Maglio, M. M., Zeytoonjian, A. A., Weller, E. E., Lauwers-Cances, V., Munshi, N., Anderson, K. C., Richardson, P. P., Facon, T., Avet-Loiseau, H., Harousseau, J.-L., Moreau, P., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., & Belhadj, K. (2017). Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. The New England journal of medicine, 376(14), 1311-1320. doi:10.1056/NEJMoa1611750


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/253470

Attal, M., Garderet, L., Roussel, M., Payen, C., Mathiot, C., Fermand, J.-P., Meuleman, N., Rollet, S., Maglio, M. M., Zeytoonjian, A. A., Weller, E. E., Lauwers-Cances, V., Munshi, N., Anderson, K. C., Richardson, P. P., Facon, T., Avet-Loiseau, H., Harousseau, J.-L., Moreau, P., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., & Belhadj, K. (2017). Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. The New England journal of medicine, 376(14), 1311-1320. doi:10.1056/NEJMoa1611750